PMID- 28683109
OWN - NLM
STAT- MEDLINE
DCOM- 20170922
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 7
DP  - 2017
TI  - 18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of
      liver-specific contrast agent Gadobenate dimeglumine.
PG  - e0180349
LID - 10.1371/journal.pone.0180349 [doi]
AB  - OBJECTIVES: To evaluate the added value of the application of the liver-specific 
      contrast phase of Gadobenate dimeglumine (Gd-BOPTA) for detection and
      characterization of liver lesions in 18F-FDG PET/MRI. METHODS: 41 patients with
      histologically confirmed solid tumors and known / suspected liver metastases or
      not classifiable lesions in 18F-FDG PET/CT were included in this study. All
      patients underwent a subsequent Gd-BOPTA enhanced 18F-FDG PET/MRI examination.
      MRI without liver-specific contrast phase (MRI1), MRI with liver-specific
      contrast phase (MRI2), 18F-FDG PET/MRI without liver-specific contrast phase
      (PET/MRI1) and with liver-specific contrast phase (PET/MRI2) were separately
      evaluated for suspect lesions regarding lesion dignity, characterization,
      conspicuity and confidence. RESULTS: PET/MRI datasets enabled correct
      identification of 18/18 patients with malignant lesions; MRI datasets correctly
      identified 17/18 patients. On a lesion-based analysis PET/MRI2 provided highest
      accuracy for differentiation of lesions into malignant and benign lesions of 98% 
      and 100%. Respective values were 95% and 100% for PET/MRI1, 93% and 96% for MRI2 
      and 91% and 93% for MRI1. Statistically significant higher diagnostic confidence 
      was found for PET/MRI2 and MRI2 datasets compared to PET/MRI1 and MRI1,
      respectively (p < 0.001). CONCLUSION: The application of the liver-specific
      contrast phase in 18F-FDG PET/MRI further increases the diagnostic accuracy and
      diagnostic confidence for correct assessment of benign and malignant liver
      lesions.
FAU - Kirchner, Julian
AU  - Kirchner J
AUID- ORCID: http://orcid.org/0000-0001-8224-3433
AD  - Department of Diagnostic and Interventional Radiology, University Dusseldorf,
      Medical Faculty, Dusseldorf, Germany.
FAU - Sawicki, Lino M
AU  - Sawicki LM
AD  - Department of Diagnostic and Interventional Radiology, University Dusseldorf,
      Medical Faculty, Dusseldorf, Germany.
FAU - Deuschl, Cornelius
AU  - Deuschl C
AD  - Institute of Diagnostic and Interventional Radiology and Neuroradiology,
      University Hospital Duisburg-Essen, Germany.
FAU - Gruneisen, Johannes
AU  - Gruneisen J
AD  - Institute of Diagnostic and Interventional Radiology and Neuroradiology,
      University Hospital Duisburg-Essen, Germany.
FAU - Beiderwellen, Karsten
AU  - Beiderwellen K
AD  - Institute of Diagnostic and Interventional Radiology and Neuroradiology,
      University Hospital Duisburg-Essen, Germany.
FAU - Lauenstein, Thomas C
AU  - Lauenstein TC
AD  - Institute of Diagnostic and Interventional Radiology and Neuroradiology,
      University Hospital Duisburg-Essen, Germany.
FAU - Herrmann, Ken
AU  - Herrmann K
AD  - Department of Nuclear Medicine, University Hospital Essen, University of
      Duisburg-Essen, Essen, Germany.
FAU - Forsting, Michael
AU  - Forsting M
AD  - Institute of Diagnostic and Interventional Radiology and Neuroradiology,
      University Hospital Duisburg-Essen, Germany.
FAU - Heusch, Philipp
AU  - Heusch P
AD  - Department of Diagnostic and Interventional Radiology, University Dusseldorf,
      Medical Faculty, Dusseldorf, Germany.
FAU - Umutlu, Lale
AU  - Umutlu L
AD  - Institute of Diagnostic and Interventional Radiology and Neuroradiology,
      University Hospital Duisburg-Essen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20170706
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Contrast Media)
RN  - 0 (Organometallic Compounds)
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - 15G12L5X8K (gadobenic acid)
RN  - 6HG8UB2MUY (Meglumine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/diagnostic imaging/metabolism/pathology
MH  - Carcinoma, Hepatocellular/*diagnostic imaging/metabolism/secondary
MH  - Cholangiocarcinoma/diagnostic imaging/metabolism/pathology
MH  - Colorectal Neoplasms/diagnostic imaging/metabolism/pathology
MH  - Contrast Media/*pharmacokinetics
MH  - Female
MH  - Fluorodeoxyglucose F18/pharmacokinetics
MH  - Humans
MH  - Liver/*diagnostic imaging/metabolism/pathology
MH  - Liver Neoplasms/*diagnostic imaging/metabolism/secondary
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Meglumine/*analogs & derivatives/pharmacokinetics
MH  - Melanoma/diagnostic imaging/metabolism/pathology
MH  - Middle Aged
MH  - Organometallic Compounds/*pharmacokinetics
MH  - Positron Emission Tomography Computed Tomography/*methods
MH  - Radiopharmaceuticals/pharmacokinetics
MH  - Sensitivity and Specificity
PMC - PMC5500282
EDAT- 2017/07/07 06:00
MHDA- 2017/09/25 06:00
CRDT- 2017/07/07 06:00
PHST- 2017/02/15 00:00 [received]
PHST- 2017/06/14 00:00 [accepted]
PHST- 2017/07/07 06:00 [entrez]
PHST- 2017/07/07 06:00 [pubmed]
PHST- 2017/09/25 06:00 [medline]
AID - 10.1371/journal.pone.0180349 [doi]
AID - PONE-D-17-06169 [pii]
PST - epublish
SO  - PLoS One. 2017 Jul 6;12(7):e0180349. doi: 10.1371/journal.pone.0180349.
      eCollection 2017.